Aspirin in the treatment and prevention of cardiovascular disease

Haemostasis

Volumn 30, Issue SUPPL. 3, 2000, Pages 1-13

  Gaziano, J Michael ^a,b,d   Skerrett, P J ^a   Buring, Julie E ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aspirin; Cerebrovascular disease; Coronary diseases; Primary prevention; Secondary prevention; Therapy

Indexed keywords

ACETYLSALICYLIC ACID;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG INDUCED DISEASE; FEMALE; HEART DEATH; HEART REINFARCTION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE;

EID: 0034487104     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054193     Document Type: Conference Paper

References (57)

1. The history of aspirin
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
3. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
4. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls
5. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein
6. Aspirin improves endothelial dysfunction in atherosclerosis
7. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
8. Aspirin protects low density lipoprotein from oxidative modification
9. Prevention of coronary thrombosis and cerebral thrombosis
10. Regular aspirin intake and acute myocardial infarction
11. Regular aspirin use and myocardial infarction
12. A case-control study of regular aspirin use and coronary deaths
13. A prospective study of aspirin use and primary prevention of cardiovascular disease in women
14. Aspirin and coronary heart disease: Findings of a prospective study
15. Aspirin use and chronic diseases: A cohort study of the elderly
16. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
17. ISIS-2: 10 Year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
18. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?
19. Geographic variation in the treatment of acute myocardial infarction: The Cooperative Cardiovascular Project
20. Patterns of practice for acute myocardial infarction in a population from ten countries
21. The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States
22. A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke
23. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
24. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction
25. Secondary prevention of vascular disease by prolonged antiplatelet treatment
26. Collaborative overview of randomised trials of antiplatelet therapy I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
27. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: A review of clinical trial results
28. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
29. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration Cooperative Study
30. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study
31. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts
32. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
33. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
34. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study
35. Aspirin use is low among United States outpatients with coronary artery disease
36. Mismedication and underutilization of aspirin in the prevention and treatment of cardiovascular disease
37. Findings from the aspirin component of the ongoing Physicians' Health Study
38. Final report on the aspirin component of the ongoing Physicians' Health Study
39. Randomised trial of prophylactic daily aspirin in British male doctors
40. Aspirin effects on mortality and morbidity in patients with diabetes mellitus
41. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
42. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
43. Overview of aspirin in the primary prevention of cardiovascular disease
44. Aspirin for the primary prevention of stroke and other major vascular events: Meta-analysis and hypotheses
45. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials
46. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - Analysis of gastrointestinal bleeding during the UK-TIA trial
47. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial Interim results
48. Adjunctive drug therapy of acute myocardial infarction - Evidence from clinical trials
49. Aspirin for transient ischemic attacks
50. Aspirin for heart patients
51. Final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products
52. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction
53. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
54. Aspirin therapy in diabetes
55. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention
56. Aspirin